Affare Sofosbuvir, chi ha vinto la lotteria
Primo farmaco efficace contro l’epatite C, il brevetto della multinazionale Gilead è reso praticamente inaccessibile ai pazienti.
News e Aggiornamenti
Storie dal Campo
MSF Italia is part of a global network delivering medical aid where it is needed most. Independent. Neutral. Impartial.
- International(English)
- Argentina(Español)
- Australia(English)
- Austria(Deutsch)
- Belgium(Nederlands/Français)
- Brazil(Português)
- Canada(English/Français)
- Czech Republic(Česky/English)
- Denmark(Dansk)
- France(Français)
- Germany(Deutsch)
- Greece(ελληνικά)
- Hong Kong(繁體中文)
- India(English)
- Ireland(English)
- Italy(Italiano)
- Japan(日本語)
- Luxembourg(Français)
- Mexico(Español)
- Myanmar(English/ မြန်မာစာ)
- Netherlands(Nederlands)
- Norway(Norsk)
- Russia(Русский)
- South Africa(English)
- South East Asia(汉语/English)
- South Korea(한국어)
- Spain(Español)
- Sweden(Svenska)
- Switzerland(Deutsch/Français)
- Turkey(Türkiye)
- United Kingdom(English)
- United Arab Emirates(English/العربية)
- United States(English)